[89Zr]Zr-PSMA-617 PET/CT in biochemical recurrence of prostate cancer: first clinical experience from a pilot study including biodistribution and dose estimates

[1]  Steffie M. B. Peters,et al.  89Zr-labeled PSMA ligands for pharmacokinetic PET imaging and dosimetry of PSMA-617 and PSMA-I&T: a preclinical evaluation and first in man , 2021, European Journal of Nuclear Medicine and Molecular Imaging.

[2]  A. Afshar-Oromieh,et al.  Radiolabeled PSMA Inhibitors , 2021, Cancers.

[3]  M. Schreckenberger,et al.  Early molecular imaging response assessment based on determination of total viable tumor burden in [68Ga]Ga-PSMA-11 PET/CT independently predicts overall survival in [177Lu]Lu-PSMA-617 radioligand therapy , 2021, European Journal of Nuclear Medicine and Molecular Imaging.

[4]  A. Drzezga,et al.  An 89Zr-Labeled PSMA Tracer for PET/CT Imaging of Prostate Cancer Patients , 2021, The Journal of Nuclear Medicine.

[5]  A. Kishan,et al.  Use and Impact of Positron Emission Tomography/Computed Tomography Prior to Salvage Radiation Therapy in Men with Biochemical Recurrence After Radical Prostatectomy: A Scoping Review. , 2021, European urology oncology.

[6]  T. Holland-Letz,et al.  Performance of [68Ga]Ga-PSMA-11 PET/CT in patients with recurrent prostate cancer after prostatectomy—a multi-centre evaluation of 2533 patients , 2021, European Journal of Nuclear Medicine and Molecular Imaging.

[7]  R. Boellaard,et al.  The Role of 89Zr-Immuno-PET in Navigating and Derisking the Development of Biopharmaceuticals , 2020, The Journal of Nuclear Medicine.

[8]  Kyung-Han Lee,et al.  89Zr-Labeled Anti-PD-L1 Antibody PET Monitors Gemcitabine Therapy-Induced Modulation of Tumor PD-L1 Expression , 2020, Journal of Nuclear Medicine.

[9]  Joon-Kee Yoon,et al.  Current Perspectives on 89Zr-PET Imaging , 2020, International journal of molecular sciences.

[10]  F. Mottaghy,et al.  Multiphasic 68Ga-PSMA PET/CT in the Detection of Early Recurrence in Prostate Cancer Patients with a PSA Level of Less Than 1 ng/mL: A Prospective Study of 135 Patients , 2020, The Journal of Nuclear Medicine.

[11]  P. Carroll,et al.  Assessment of 68Ga-PSMA-11 PET Accuracy in Localizing Recurrent Prostate Cancer: A Prospective Single-Arm Clinical Trial. , 2019, JAMA oncology.

[12]  A. Buck,et al.  68Ga-PSMA I&T PET/CT for primary staging of prostate cancer , 2019, Nuklearmedizin.

[13]  D. Murphy,et al.  Advances in Urologic Imaging: Prostate-Specific Membrane Antigen Ligand PET Imaging. , 2018, The Urologic clinics of North America.

[14]  Sören Mattsson,et al.  IDAC-Dose 2.1, an internal dosimetry program for diagnostic nuclear medicine based on the ICRP adult reference voxel phantoms , 2017, EJNMMI Research.

[15]  O. Boerman,et al.  89Zr-Immuno-Positron Emission Tomography in Oncology: State-of-the-Art 89Zr Radiochemistry , 2017, Bioconjugate chemistry.

[16]  Steven P. Rowe,et al.  PSMA Ligands for PET Imaging of Prostate Cancer , 2017, The Journal of Nuclear Medicine.

[17]  Matthias Eiber,et al.  177Lu-PSMA Radioligand Therapy for Prostate Cancer , 2017, The Journal of Nuclear Medicine.

[18]  H. Kauczor,et al.  Diagnostic performance of 68Ga-PSMA-11 (HBED-CC) PET/CT in patients with recurrent prostate cancer: evaluation in 1007 patients , 2017, European Journal of Nuclear Medicine and Molecular Imaging.

[19]  Bernd J. Krause,et al.  68Ga-PSMA PET/CT: Joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0 , 2017, European Journal of Nuclear Medicine and Molecular Imaging.

[20]  B. Hadaschik,et al.  F-18 labelled PSMA-1007: biodistribution, radiation dosimetry and histopathological validation of tumor lesions in prostate cancer patients , 2016, European Journal of Nuclear Medicine and Molecular Imaging.

[21]  U. Haberkorn,et al.  The Rise of PSMA Ligands for Diagnosis and Therapy of Prostate Cancer , 2016, The Journal of Nuclear Medicine.

[22]  U. Haberkorn,et al.  PSMA-Targeted Radionuclide Therapy of Metastatic Castration-Resistant Prostate Cancer with 177Lu-Labeled PSMA-617 , 2016, The Journal of Nuclear Medicine.

[23]  U. Haberkorn,et al.  Radiation dosimetry of 68Ga-PSMA-11 (HBED-CC) and preliminary evaluation of optimal imaging timing , 2016, European Journal of Nuclear Medicine and Molecular Imaging.

[24]  Tim Holland-Letz,et al.  The Theranostic PSMA Ligand PSMA-617 in the Diagnosis of Prostate Cancer by PET/CT: Biodistribution in Humans, Radiation Dosimetry, and First Evaluation of Tumor Lesions , 2015, The Journal of Nuclear Medicine.

[25]  Christoph Hoeschen,et al.  Electron specific absorbed fractions for the adult male and female ICRP/ICRU reference computational phantoms , 2012, Physics in medicine and biology.

[26]  W. Heston,et al.  Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer , 2004, Journal of cellular biochemistry.

[27]  U. Haberkorn,et al.  Dosimetry for 177Lu-DKFZ-PSMA-617: a new radiopharmaceutical for the treatment of metastatic prostate cancer , 2015, European Journal of Nuclear Medicine and Molecular Imaging.